EULAR Evidence-based Recommendations on the Management of Systemic Glucocorticoid Therapy in Rheumatic Diseases

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2007 Jul 31

PMID 17660219

Citations 107

Authors

J N Hoes

J W G Jacobs

M Boers

D Boumpas

F Buttgereit

N Caeyers

E H Choy

M Cutolo

J A P Da Silva

G Esselens

L Guillevin

I Hafstrom

J R Kirwan

J Rovensky

A Russell

K G Saag

B Svensson

R Westhovens

H Zeidler

J W J Bijlsma

Affiliations

Soon will be listed here.

Abstract

Objective: To develop evidence-based recommendations for the management of systemic glucocorticoid (GC) therapy in rheumatic diseases.

Methods: The multidisciplinary guideline development group from 11 European countries, Canada and the USA consisted of 15 rheumatologists, 1 internist, 1 rheumatologist-epidemiologist, 1 health professional, 1 patient and 1 research fellow. The Delphi method was used to agree on 10 key propositions related to the safe use of GCs. A systematic literature search of PUBMED, EMBASE, CINAHL, and Cochrane Library was then used to identify the best available research evidence to support each of the 10 propositions. The strength of recommendation was given according to research evidence, clinical expertise and perceived patient preference.

Results: The 10 propositions were generated through three Delphi rounds and included patient education, risk factors, adverse effects, concomitant therapy (ie, non-steroidal anti-inflammatory drugs, gastroprotection and cyclo-oxygenase-2 selective inhibitors, calcium and vitamin D, bisphosphonates) and special safety advice (ie, adrenal insufficiency, pregnancy, growth impairment).

Conclusion: Ten key recommendations for the management of systemic GC-therapy were formulated using a combination of systematically retrieved research evidence and expert consensus. There are areas of importance that have little evidence (ie, dosing and tapering strategies, timing, risk factors and monitoring for adverse effects, perioperative GC-replacement) and need further research; therefore also a research agenda was composed.

Citing Articles

Screening and diagnosis of sarcopenia in rheumatic and musculoskeletal diseases: findings from a cross-sectional study.

Pardali E, Kontouli K, Gkouvi A, Tsakmaki I, Patrikiou E, Karapli M Rheumatol Int. 2025; 45(3):67.

PMID: 40019564 PMC: 11870930. DOI: 10.1007/s00296-025-05821-7.

Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan.

Iki M, Fujimori K, Okimoto N, Nakatoh S, Tamaki J, Ishii S Osteoporos Int. 2024; 36(1):81-92.

PMID: 39432088 DOI: 10.1007/s00198-024-07284-1.

Vignette-based comparative analysis of ChatGPT and specialist treatment decisions for rheumatic patients: results of the Rheum2Guide study.

Labinsky H, Nagler L, Krusche M, Griewing S, Aries P, Kroiss A Rheumatol Int. 2024; 44(10):2043-2053.

PMID: 39126460 PMC: 11392980. DOI: 10.1007/s00296-024-05675-5.

Addressing Glucocorticoid-Related Problems with the Clinical Pharmacist Collaboration in Rheumatology Practice: A Prospective Follow-Up Study.

Bahap-Kara M, Sariyildiz E, Yardimci G, Karadag O, Bayraktar-Ekincioglu A Rheumatol Ther. 2024; 11(4):1043-1055.

PMID: 38926304 PMC: 11264585. DOI: 10.1007/s40744-024-00692-z.

Prospective assessment of glucocorticoid toxicity in rheumatology practice: a focus on the glucocorticoid toxicity index.

Bahap-Kara M, Sariyildiz E, Zengin H, Karadag O, Bayraktar-Ekincioglu A Rheumatology (Oxford). 2024; 64(3):1010-1018.

PMID: 38781534 PMC: 11879322. DOI: 10.1093/rheumatology/keae288.

References

Da Silva J, Jacobs J, Kirwan J, Boers M, Saag K, Ines L . Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2005; 65(3):285-93. PMC: 1798053. DOI: 10.1136/ard.2005.038638. View

van Staa T, Laan R, Barton I, Cohen S, Reid D, Cooper C . Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003; 48(11):3224-9. DOI: 10.1002/art.11283. View

Simon D, Lucidarme N, Prieur A, Ruiz J, Czernichow P . Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol. 2003; 30(11):2492-9. View

Pirson Y, Van Lierde M, Ghysen J, Squifflet J, Alexandre G, Van Ypersele De Strihou C . Retardation of fetal growth in patients receiving immunosuppressive therapy. N Engl J Med. 1985; 313(5):328. DOI: 10.1056/NEJM198508013130516. View

Pinsky L, DIGEORGE A . CLEFT PALATE IN THE MOUSE: A TERATOGENIC INDEX OF GLUCOCORTICOID POTENCY. Science. 1965; 147(3656):402-3. DOI: 10.1126/science.147.3656.402. View

Silvestri A, Galetta P, Cerquetani E, Marazzi G, Patrizi R, Fini M . Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003; 24(21):1928-32. DOI: 10.1016/j.ehj.2003.08.016. View

Allen D, GOLDBERG B . Stimulation of collagen synthesis and linear growth by growth hormone in glucocorticoid-treated children. Pediatrics. 1992; 89(3):416-21. View

Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E . Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2003; (4):CD002296. DOI: 10.1002/14651858.CD002296. View

Homik J, Suarez-Almazor M, Shea B, Cranney A, Wells G, Tugwell P . Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000; (2):CD000952. PMC: 7046131. DOI: 10.1002/14651858.CD000952. View

10.

Al-Mutair A, Bahabri S, Al-Mayouf S, Al-Ashwal A . Efficacy of recombinant human growth hormone in children with juvenile rheumatoid arthritis and growth failure. J Pediatr Endocrinol Metab. 2000; 13(7):899-905. DOI: 10.1515/jpem.2000.13.7.899. View

11.

Allen D . Growth hormone therapy for short stature: is the benefit worth the burden?. Pediatrics. 2006; 118(1):343-8. DOI: 10.1542/peds.2006-0329. View

12.

Kvien T, Haugeberg G, Uhlig T, Falch J, Halse J, Lems W . Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis. Ann Rheum Dis. 2000; 59(10):805-11. PMC: 1753011. DOI: 10.1136/ard.59.10.805. View

13.

Allen D, Julius J, Breen T, Attie K . Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab. 1998; 83(8):2824-9. DOI: 10.1210/jcem.83.8.5036. View

14.

Bechtold S, Ripperger P, Hafner R, Said E, Schwarz H . Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr. 2003; 143(4):512-9. DOI: 10.1067/S0022-3476(03)00390-1. View

15.

. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001; 108(3):776-89. DOI: 10.1542/peds.108.3.776. View

16.

Shekelle P, Woolf S, Eccles M, Grimshaw J . Clinical guidelines: developing guidelines. BMJ. 1999; 318(7183):593-6. PMC: 1115034. DOI: 10.1136/bmj.318.7183.593. View

17.

Grote F, van Suijlekom-Smit L, Mul D, Hop W, Ten Cate R, Oostdijk W . Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia. Arch Dis Child. 2005; 91(1):56-60. PMC: 2083074. DOI: 10.1136/adc.2004.069138. View

18.

Boumpas D, Chrousos G, Wilder R, Cupps T, Balow J . Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993; 119(12):1198-208. DOI: 10.7326/0003-4819-119-12-199312150-00007. View

19.

Schatz M, Patterson R, Zeitz S, ORourke J, Melam H . Corticosteroid therapy for the pregnant asthmatic patient. JAMA. 1975; 233(7):804-7. View

20.

Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther K . EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2004; 64(5):669-81. PMC: 1755499. DOI: 10.1136/ard.2004.028886. View